Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) Gross Margin (2019 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Gross Margin for 5 consecutive years, with 95.54% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Margin rose 691.0% year-over-year to 95.54%, compared with a TTM value of 84.52% through Dec 2025, up 1594.0%, and an annual FY2025 reading of 84.52%, up 1594.0% over the prior year.
  • Gross Margin was 95.54% for Q4 2025 at Zevra Therapeutics, roughly flat from 95.26% in the prior quarter.
  • Across five years, Gross Margin topped out at 100.0% in Q3 2021 and bottomed at 6.25% in Q2 2022.
  • Average Gross Margin over 5 years is 79.86%, with a median of 94.94% recorded in 2023.
  • The sharpest move saw Gross Margin skyrocketed 9826bps in 2023, then crashed -7232bps in 2024.
  • Year by year, Gross Margin stood at 97.71% in 2021, then grew by 1bps to 99.05% in 2022, then dropped by -9bps to 90.5% in 2023, then dropped by -2bps to 88.63% in 2024, then grew by 8bps to 95.54% in 2025.
  • Business Quant data shows Gross Margin for ZVRA at 95.54% in Q4 2025, 95.26% in Q3 2025, and 52.2% in Q2 2025.